Revenue for Q3 2024 declined slightly year-over-year, but operating losses narrowed and key product milestones were achieved, including test series production and a new patent application. Cash position remains strong with a 95% equity ratio.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.